View Older Stories

Nov 3, 2025 04:44PM Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY25 Guidance

Oct 14, 2025 08:06AM Myriad Genetics adds two genes to carrier screening panel

Oct 3, 2025 04:28PM Myriad Genetics names CFO as principal accounting officer

Sep 23, 2025 08:01AM Myriad Genetics partners with SOPHiA GENETICS on liquid biopsy test

Aug 19, 2025 07:38AM UBS Reiterates Neutral Rating on Myriad Genetics (MYGN)

Aug 7, 2025 05:05AM Myriad Genetics (MYGN) call put ratio 6.2 calls to 1 put with a focus on August 7 and February 5 calls

Aug 5, 2025 04:36PM Myriad Genetics (MYGN) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY25 Guidance

Jul 25, 2025 12:02PM Piper Sandler: 'Opportunities to Buy Dislocated Stocks after Prints'

May 21, 2025 12:43PM Scotiabank Downgrades Myriad Genetics (MYGN) to Sector Perform

May 7, 2025 07:03AM Myriad Genetics (MYGN) PT Lowered to $5 at Jefferies

May 7, 2025 12:46AM Myriad Genetics (MYGN) Tops Q1 EPS by 3c ; Offers Guidance

Apr 21, 2025 04:05PM Myriad Genetics (MYGN) Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Apr 7, 2025 08:03AM Myriad Genetics (MYGN) Appoints Brian Donnelly as Chief Commercial Officer

Apr 1, 2025 06:53AM Myriad Genetics (MYGN) PT Lowered to $20 at Scotiabank

Mar 12, 2025 04:09AM Piper Sandler Upgrades Myriad Genetics (MYGN) to Overweight

Mar 11, 2025 12:35PM Myriad Genetics (MYGN) PT Lowered to $16 at Morgan Stanley

Feb 25, 2025 05:13AM Myriad Genetics (MYGN) PT Lowered to $12 at JPMorgan

Feb 25, 2025 05:09AM Myriad Genetics (MYGN) PT Lowered to $11 at Jefferies

Feb 24, 2025 05:02PM Myriad Genetics (MYGN) Reports In-Line Q4 EPS

Feb 24, 2025 04:07PM Myriad Genetics (MYGN) Announces Senior Leadership Transition

Feb 12, 2025 08:44AM Craig-Hallum Starts Myriad Genetics (MYGN) at Buy, 'We would be buying MYGN'

Feb 5, 2025 04:15PM Myriad Genetics (MYGN) Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Feb 5, 2025 08:33AM Myriad Genetics (MYGN) and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Jan 23, 2025 08:33AM Myriad Genetics (MYGN) Introduces Online Prenatal Genetic Testing Resource

Jan 15, 2025 08:32AM Myriad Genetics (MYGN) Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

Dec 10, 2024 04:13PM Myriad Genetics (MYGN) Expands Board of Directors with Election of Mark S. Davis as New Board Member

Dec 10, 2024 03:32AM UBS Starts Myriad Genetics (MYGN) at Neutral

Dec 9, 2024 06:26AM Leerink Partners Downgrades Myriad Genetics (MYGN) to Market Perform

Nov 13, 2024 08:07AM Myriad Genetics (MYGN) Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

Nov 13, 2024 07:20AM Myriad Genetics (MYGN) PT Lowered to $24 at Scotiabank

Nov 7, 2024 04:46PM Myriad Genetics (MYGN) Tops Q3 EPS by 4c, provides guidance

Nov 4, 2024 09:24AM TD Cowen Reiterates Hold Rating on Myriad Genetics (MYGN)

Nov 4, 2024 08:40AM Myriad Genetics (MYGN) Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

Oct 16, 2024 09:03AM Myriad Genetics (MYGN) and jscreen Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

Oct 15, 2024 09:01AM Myriad Genetics (MYGN) and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

Oct 14, 2024 10:25AM Scotiabank Reiterates Sector Outperform Rating on Myriad Genetics (MYGN)

Oct 11, 2024 06:07AM Stephens Reiterates Equal Weight Rating on Myriad Genetics (MYGN)

Oct 11, 2024 06:04AM Myriad Genetics (MYGN) PT Raised to $40 at Leerink Partners

Oct 10, 2024 05:44AM JPMorgan Reiterates Underweight Rating on Myriad Genetics (MYGN)

Oct 10, 2024 05:31AM BofA Securities Reiterates Underperform Rating on Myriad Genetics (MYGN)

Oct 8, 2024 04:05PM Myriad Genetics (MYGN) Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Oct 1, 2024 06:47AM Wells Fargo Offers 10 High-Conviction Long/Short Ideas for Q4, Comments on tesla (TSLA): 'We see declining delivery growth'

Sep 19, 2024 03:56AM Morgan Stanley Starts Myriad Genetics (MYGN) at Equalweight

Aug 21, 2024 05:13AM Myriad Genetics (MYGN) PT Raised to $40 at Wolfe Research

Aug 13, 2024 06:55AM Myriad Genetics (MYGN) PT Raised to $34 at Scotiabank

Aug 12, 2024 12:04PM Myriad Genetics (MYGN) PT Raised to $22 at Jefferies

Aug 7, 2024 11:09AM Myriad Genetics (MYGN) PT Raised to $30 at TD Cowen

Aug 1, 2024 04:09PM Myriad Genetics (MYGN) Completes Sale of EndoPredict Business to Eurobio Scientific, Advances International Reorganization

Jul 24, 2024 11:00PM These stocks offer you exposure to rising demand for fertility treatment – Barclays

Jul 9, 2024 09:01AM Myriad Genetics (MYGN) Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

View Older Stories